Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis B and C: current therapy]

H R Bruch1, U Höhner, R Müller

  • 1Medizinische Klinik, Gastroenterologie-Hepatologie, Krankenhaus Siegburg.

Praxis
|November 24, 1998
PubMed
Summary

Treatment for viral hepatitis B and C involves symptomatic care for acute cases and therapies like interferon (IFN)-alpha and nucleoside analogues for chronic infections. Combination therapies show promise for relapsed patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2.

Journal of hepatology·1993
Same author

Left ventricular filling behaviour in ultra endurance and amateur athletes: a stress Doppler-echo study.

International journal of sports medicine·1992
Same author

Analysis of temperature-sensitive functions of Fos: lack of a correlation between transformation and TRE-dependent trans-activation.

Oncogene·1992
Same author

Purification and properties of 4-halobenzoate-coenzyme A ligase from Pseudomonas sp. CBS3.

Biological chemistry Hoppe-Seyler·1992
Same author

Microtubule-associated proteins 1A and LC2. Two proteins encoded in one messenger RNA.

The Journal of biological chemistry·1992
Same author

Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively.

Genomics·1992

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Context:

  • Viral hepatitis B and C present significant global health challenges.
  • Acute viral hepatitis B management is primarily symptomatic, with liver transplantation reserved for fulminant cases.
  • Chronic hepatitis B and C infections require specific antiviral interventions.

Purpose:

  • To outline current and emerging treatment strategies for acute and chronic viral hepatitis B and C.
  • To evaluate the efficacy of interferon (IFN)-alpha and nucleoside analogues in managing these viral infections.
  • To explore the potential of combination therapies for difficult-to-treat cases.

Summary:

  • Interferon (IFN)-alpha achieves sustained response rates of 30-40% in chronic hepatitis B.
  • Nucleoside analogues offer alternatives for non-responders or patients with cirrhosis and immunosuppression in hepatitis B.
  • Interferon (IFN)-alpha can reduce chronicity in acute hepatitis C and is recommended for specific chronic hepatitis C patient profiles.
  • Sustained response rates for chronic hepatitis C with IFN-alpha are below 20%, with retreatment and combination therapy (IFN-alpha plus ribavirin) showing potential.

Impact:

  • Current treatments for chronic hepatitis B and C offer moderate efficacy, highlighting the need for improved therapeutic options.
  • The emergence of nucleoside analogues and combination therapies may improve outcomes for non-responders and relapsed patients.
  • Further research into novel antiviral agents and treatment regimens is crucial for managing viral hepatitis effectively.

Related Experiment Videos